Celltrion Pharm FY 2025 Annual ReportBeta
Celltrion Pharm annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 16, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Celltrion Pharm FY 2025 Annual Report Analysis
Business Overview
- • Pharmaceutical revenue KRW 536.4B in FY2025, 12.3% increase YoY driven by chemical drugs KRW 200.6B (+7.8%) and biosimilars KRW 130.6B (+50.8%)
- • PFS (Prefilled Syringe) biosimilar production line certified by US and EU GMP, located in Ochang facility with 2,315㎡ area
Management Discussion & Analysis
- • Revenue KRW 536.4B (+12.3% YoY); Operating profit KRW 56.1B (+50.7%); Net income KRW 38.8B (+76.4%)
- • Bio-pharmaceutical segment sales KRW 130.6B, up 50.8% YoY; driven by strong growth beyond Ramsima
Risk Factors
- • KRW 183.6M pre-tax income sensitivity to 10% USD exchange rate change at FY2025 end
- • KRW 142B variable-rate borrowings exposed to interest rate risk with ±KRW 1.42B profit/loss impact per 1% rate change
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding